Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EYPT Stock 12 Month Forecast
Average Price Target
$31.50
▲(97.00% Upside)
| Highest Price Target$43.00 | Average Price Target$31.50 | Lowest Price Target$20.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$43
Buy
168.92%
Upside
Reiterated
12/11/25
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD TherapyWe are hosting Dr. Tarek S. Hassan, MD, today at 1:30 PM ET, to assess which candidates have the potential to be truly paradigm changing. Register HERE. Address 1. What are the unmet needs in wet AMD despite the availability of Vabysmo (RHHBY, Not rated) and Eylea HD (REGN, Not rated)? 2. What do clinicians expect from upcoming Ph3 updates in wet AMD, including: (1) Axpaxli's SOL-1 trial in 1Q26; (2) Duravyu's LUGANO trial in mid-26, with LUCIA reading out shortly after; (3) sura-vec's ATMOSPHERE and ASCENT trials in 4Q26? 3. EYPT has pursued a well-established regulatory path for wet AMD approval, while OCUL has adopted a more innovative approach. What are the relative risks and benefits of these strategies? 4.
Mizuho Securities
$33
Buy
106.38%
Upside
Reiterated
12/09/25
H.C. Wainwright
$23
Buy
43.84%
Upside
Reiterated
11/20/25
EyePoint Pharmaceuticals: Positive DSMC Recommendations and Promising Clinical Trials Reinforce Buy RatingValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.87B, which includes a discounted cash flow (DCF) based asset value of $1.46B for DURAVYU (with 70% probability of approval), with a 15% discount rate and 2% terminal growth rate, and $402M cash. Assuming 84.1M shares outstanding by the end of 3Q26, this yields a value of roughly $23 per share.
TD Cowen
$25→$20
Buy
25.08%
Upside
Reiterated
11/05/25
RBC Capital
$39
Buy
143.90%
Upside
Reiterated
11/05/25
Scotiabank
$18
Buy
12.57%
Upside
Reiterated
08/07/25
Guggenheim
$68
Buy
325.27%
Upside
Reiterated
08/06/25
With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.
J.P. Morgan
$26
Buy
62.60%
Upside
Reiterated
05/27/25
Cantor Fitzgerald
―
Buy
―
Reiterated
02/05/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$43
Buy
168.92%
Upside
Reiterated
12/11/25
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD TherapyWe are hosting Dr. Tarek S. Hassan, MD, today at 1:30 PM ET, to assess which candidates have the potential to be truly paradigm changing. Register HERE. Address 1. What are the unmet needs in wet AMD despite the availability of Vabysmo (RHHBY, Not rated) and Eylea HD (REGN, Not rated)? 2. What do clinicians expect from upcoming Ph3 updates in wet AMD, including: (1) Axpaxli's SOL-1 trial in 1Q26; (2) Duravyu's LUGANO trial in mid-26, with LUCIA reading out shortly after; (3) sura-vec's ATMOSPHERE and ASCENT trials in 4Q26? 3. EYPT has pursued a well-established regulatory path for wet AMD approval, while OCUL has adopted a more innovative approach. What are the relative risks and benefits of these strategies? 4.
Mizuho Securities
$33
Buy
106.38%
Upside
Reiterated
12/09/25
H.C. Wainwright
$23
Buy
43.84%
Upside
Reiterated
11/20/25
EyePoint Pharmaceuticals: Positive DSMC Recommendations and Promising Clinical Trials Reinforce Buy RatingValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.87B, which includes a discounted cash flow (DCF) based asset value of $1.46B for DURAVYU (with 70% probability of approval), with a 15% discount rate and 2% terminal growth rate, and $402M cash. Assuming 84.1M shares outstanding by the end of 3Q26, this yields a value of roughly $23 per share.
TD Cowen
$25→$20
Buy
25.08%
Upside
Reiterated
11/05/25
RBC Capital
$39
Buy
143.90%
Upside
Reiterated
11/05/25
Scotiabank
$18
Buy
12.57%
Upside
Reiterated
08/07/25
Guggenheim
$68
Buy
325.27%
Upside
Reiterated
08/06/25
With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.
J.P. Morgan
$26
Buy
62.60%
Upside
Reiterated
05/27/25
Cantor Fitzgerald
―
Buy
―
Reiterated
02/05/25
Best Analysts Covering EyePoint Pharmaceuticals
1 Month
xxx
Success Rate
7/14 ratings generated profit
Average Return
-4.29%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -4.29% per trade.
3 Months
xxx
Success Rate
12/19 ratings generated profit
Average Return
+20.59%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +20.59% per trade.
1 Year
Success Rate
10/11 ratings generated profit
Average Return
+72.46%
reiterated a buy rating 5 days ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +72.46% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+85.85%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +85.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EYPT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
15
12
14
18
14
Buy
0
0
0
0
0
Hold
12
9
9
10
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
21
23
28
23
Each month's total comprises the sum of three months' worth of ratings.
EYPT Financial Forecast
EYPT Stock Forecast FAQ
What is EYPT’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 31.50.
What is EYPT’s upside potential, based on the analysts’ average price target?
EyePoint Pharmaceuticals Inc has 97.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EYPT a Buy, Sell or Hold?
EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is EyePoint Pharmaceuticals Inc’s price target?
The average price target for EyePoint Pharmaceuticals Inc is 31.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $43.00 ,the lowest forecast is $20.00. The average price target represents 97.00% Increase from the current price of $15.99.
The highest analyst price target is $43.00 ,the lowest forecast is $20.00. The average price target represents 97.00% Increase from the current price of $15.99.
What do analysts say about EyePoint Pharmaceuticals Inc?
EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of EYPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.